<DOC>
	<DOCNO>NCT01225861</DOCNO>
	<brief_summary>The primary objective study descriptive analysis incidence &amp; severity side effect &amp; reason discontinuation treatment chronic pain transdermal analgesic Buprenorphine patch .</brief_summary>
	<brief_title>Prospective Study Use Transdermal Analgesic Buprenorphine Patches Chronic Pain UK</brief_title>
	<detailed_description>750 patient treat transdermal Buprenorphine patch chronic pain include study . About 20 % patient aim patch-naive , ie receive first prescription transdermal analgesic patch within 1 month inclusion observational study . Furthermore study include 25 % cancer patient treat chronic pain order ensure appropriate mix patient population .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>Inclusion Criteria Patient age &gt; 18 Patient treat transdermal Buprenorphine The patient able answer patient 's survey &amp; estimate overall survival minimum 6 month The patient give his/her informed , write consent participate study Exclusion Criteria Patient Age &lt; 18 Patient less 6 month survival expectancy Patient unable answer patient survey whatever reason feasible form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>